<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586365</url>
  </required_header>
  <id_info>
    <org_study_id>2006-P-001670</org_study_id>
    <nct_id>NCT00586365</nct_id>
  </id_info>
  <brief_title>Naproxen for the Prevention of HO After Complex Elbow Trauma</brief_title>
  <acronym>Naproxen</acronym>
  <official_title>Effectiveness of Naproxen for the Prevention of Heterotopic Ossification After Complex Elbow Trauma: a Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complex elbow fractures can lead to formation of new bone (called Heterotopic ossification).
      This new bone is unwanted and it can restrict motion. This research study is being done to
      learn more about the effect of the drug naproxen, on unwanted formation of new bone around
      the elbow as it heals after a fracture. Naproxen belongs to a class of drugs called NSAIDs
      which stands for non-steroidal anti-inflammatory drugs.

      Several research studies suggest that NSAIDs such as Naproxen can prevent the unwanted
      formation of new bone around the hip. The effect of NSAIDS on the formation of bone around
      the elbow has not been studied as well as it has been studied for their effect on the hip.

      The drug, Naproxen is approved by the US food and drug administration (FDA) for sale but ot
      specifically for the treatment of heterotopic ossification.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Too difficult to satisfy all the inclusion criteria.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>There is no difference in ulnohumeral flexion</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heterotopic Ossification</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive 500 mg Naproxen twice a day for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will not receive naproxen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>500 mg Naproxen twice a day for two weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged 18 years or greater

          2. Operative treatment of one of the following injuries

               -  An elbow dislocation with or without associated fractures

               -  An olecranon fracture-dislocation, but not simple olecranon fractures

               -  A distal humerus fracture

        Exclusion Criteria:

          1. An existing diagnosis of one of the following conditions

               -  Injury to the central nervous system, thorax, or abdomen precluding the immediate
                  use of non-steroidal anti-inflammatory medications

               -  Fracture of any long bone since non-steroidal anti-inflammatory medications may
                  increase the risk of nonunion

               -  History of gastritis, peptic ulcer disease, or upper gastrointestinal bleeding

               -  Impaired renal function (creatinine &gt; 2.0), hypovolemia, heart failure, high
                  blood pressure ( &gt; 160/90), fluid retention, asthma, liver dysfunction (bilirubin
                  &gt; 2.0), or a coagulation disorder

               -  Allergy to non-steroidal anti-inflammatory medications

               -  Asthma, nasal polyps, urticaria, and hypotension associated with the use of
                  NSAIDs

               -  Considerable dehydration

          2. Pregnant or breast-feeding women

          3. Concomitant use of one of the following drugs:

               -  Aspirin

               -  Other naproxen products (ec-naprosyn, anaprox, anaprox ds, naprosyn suspension,
                  aleve)

               -  Methotrexate

               -  Diuretics (thiazides / furosemide)

               -  ACE-inhibitors (captopril, enalapril, ramipril etc.)

               -  Beta-blockers (propanolol etc.)

               -  Probenecid (for gout or hyperuricemia)

               -  H2-blockers, sucralfate and intensive antacid therapy

               -  Lithium

               -  Anticoagulants / Warfarin (coumadin, waran, jantoven etc.)

               -  Sulfonamides

               -  Anticonvulsant medication (peganone, mesantoin, cerebyx, dilantin, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ring, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mass General</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Viola RW, Hastings H 2nd. Treatment of ectopic ossification about the elbow. Clin Orthop Relat Res. 2000 Jan;(370):65-86. Review.</citation>
    <PMID>10660703</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David C. Ring, MD</investigator_full_name>
    <investigator_title>Director of Research, Hand Service</investigator_title>
  </responsible_party>
  <keyword>complex elbow trauma</keyword>
  <keyword>prevention</keyword>
  <keyword>complication</keyword>
  <keyword>naproxen</keyword>
  <keyword>NSAIDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ossification, Heterotopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

